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Abstract
Factors that drive prostate cancer progression remain poorly defined, thus hindering the 
development of new therapeutic strategies. Disseminated tumors are treated through regimens that 
ablate androgen signaling, as prostate cancer cells require androgen for growth and survival. 
However, recurrent, incurable tumors that have bypassed the androgen requirement ultimately 
arise. This study reveals that the Brm ATPase, a component of selected SWI/SNF complexes, has 
significant antiproliferative functions in the prostate that protect against these transitions. First, we 
show that targeted ablation of Brm is causative for the development of prostatic hyperplasia in 
mice. Second, in vivo challenge revealed that Brm−/− epithelia acquire the capacity for lobe-
specific, castration-resistant cellular proliferation. Third, investigation of human specimens 
revealed that Brm mRNA and protein levels are attenuated in prostate cancer. Fourth, Brm down-
regulation was associated with an increased proliferative index, consistent with the mouse model. 
Lastly, gene expression profiling showed that Brm loss alters factors upstream of E2F1; this was 
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confirmed in murine models, wherein Brm loss induced E2F1 deregulation in a tissue-specific 
manner. Combined, these data identify Brm as a major effector of serum androgen–induced 
proliferation in the prostate that is disrupted in human disease, and indicate that loss of Brm 
confers a proliferative advantage in prostate cancer.
Introduction
SWI/SNF chromatin remodeling complexes are critical mediators of transcriptional control, 
as manifest through their ability to mobilize nucleosomes (1, 2). SWI/SNF complexes are 
recruited to chromatin by sequence-specific transcription factors, and therein, regulate gene 
expression by either promoting nucleosome dispersion or condensation (3, 4). To control 
this process, it is increasingly apparent that the specificity of SWI/SNF function is dictated 
by biochemical diversity in subunit composition, and that imbalances in subunit expression 
can induce significant, often tissue-specific biological consequence (3, 5–8).
SWI/SNF complexes consist of a central ATPase (Brg1 or Brm), the function of which is 
required for nucleosome repositioning, a cohort of ‘‘core’’ subunits that are required to 
reconstitute SWI/SNF function in vitro (BAF47/INI1, BAF155, and BAF170), and 
combinatorial assembly of six to eight additional BAF (Brg1-associated factor) subunits that 
confer specificity of function to individual SWI/SNF complexes (3–5). Despite the general 
requirement of the central ATPase for SWI/SNF function, genetic analyses revealed 
remarkable functional heterogeneity between Brm and Brg1. For example, loss of Brg1 is an 
embryonic lethal event (9), whereas Brm−/− mice are viable and develop normally (10). 
Subsequent studies using conditional deletion of Brg1 revealed divergent roles of this 
ATPase for skin development, limb morphogenesis, erythropoiesis, vasculature, gliogenesis, 
neural stem/progenitor cells, and T-cell development (9, 11–15). Although few phenotypes 
have been detected in Brm−/− mice, these animals are up to 15% heavier than their wild-
type littermates, and show the enlargement of selected organs (e.g., liver, kidney, heart) but 
reductions in others (spleen, testes; ref. 16). Thus, despite the shared capacity of Brg1 and 
Brm to confer SWI/SNF activity, the ATPases seem to serve distinct biological functions.
In cells of prostatic origin, SWI/SNF proved capable of regulating the androgen receptor 
(AR), a ligand-dependent transcription factor that is a major effector of prostate cancer 
growth and progression. AR is the first-line therapeutic target for disseminated prostate 
cancer, as prostate cancer cells are exquisitely dependent on AR signaling (17, 18). Ligand 
(androgen) activation of AR induces rapid dimerization and nuclear translocation of the 
protein, which binds to DNA at androgen-responsive elements and induces a program of 
gene transcription in prostate cancer cells that results in cell survival and proliferation (19). 
In addition, AR directs the expression of secretory products that are used clinically to 
monitor prostate cancer growth and progression (i.e., prostate-specific antigen; refs. 20, 21). 
Using in vitro models, it was previously shown that AR requires SWI/SNF to induce gene 
expression on prostate-specific target genes, and that the receptor shows a preference in 
transient assays for Brm-induced SWI/SNF action (22, 23). Similarly, it was shown in cell-
based assays that Brm is the predominant ATPase recruited to sites of AR action after 
androgen stimulation (22, 23). Through these actions, it was hypothesized that Brm-
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mediated AR signaling supports androgen-dependent transcriptional activation in the context 
of the prostate. In prostate cancer therapy, engagement of AR signaling is targeted through 
the use of regimens that either deprive the receptor of ligand (androgen ablation) or through 
the use of direct AR antagonists (17, 19, 24). Although these strategies result in tumor 
remission, recurrent tumors arise within 2 to 3 years in which AR action is restored despite 
the absence of the ligand (25). Transition to this therapy-resistant phase of tumor 
progression represents the incurable stage of disease; thus, it is imperative to discern the 
signaling pathways that influence AR signaling in the prostate. Given the importance of 
SWI/SNF in controlling AR action in vitro, the present study interrogated the consequence 
of the Brm ATPase in the prostate using genetically defined in vivo models and analyses of 
human prostate cancer tumors.
Materials and Methods
Mice, xenografts, and human specimens
Targeted deletion of Brm was previously described (16). Animals were bred and maintained 
at the Laboratory Animal Medical Services of University of Cincinnati, and tracked by the 
Institutional Animal Care and Use Committee. Mice were obtained from (Brm+/− × Brm+/
−) offspring. Genotypes were determined as previously described (16). Prostates were 
resected after sacrifice using standard methods, and immediately dissected into the anterior, 
ventral, and dorsolateral lobes. Dissected tissues were snap-frozen (for protein or RNA 
collection) or were suspended in 10% neutral buffered formalin and paraffin embedded. For 
acquisition of human tissue, unidentified specimens from radical prostatectomy were 
obtained from the University of Cincinnati, Department of Pathology tissue bank, in 
accordance with Institutional Review Board approval. Tissue microarrays containing benign 
and malignant tissue cores were obtained from U.S. Biomax (PR801).
Castration/re-supplementation studies
Castration/re-supplementation studies were performed as indicated using standard 
procedures. Briefly, 12-week-old male mice were castrated under anesthesia, recovered for 
14 days, then randomized into cohorts that received a daily subcutaneous injection of 
testosterone propionate (3 mg/mL, 100 µL) dissolved in sesame oil or vehicle control. On 
the third day, mice received two i.p. injections of 5-bromo-2-deoxyuridine [150 mg/kg 
bromodeoxyuridine (BrdUrd); Sigma]. Mice were sacrificed after 7 days of injection and 
prostates immediately resected.
Histology and immunohistochemistry
H&E staining was performed using standard methodologies. For Brm 
immunohistochemistry, tissue samples were deparaffinized, antigens retrieved using antigen 
unmasking solution (Vector Laboratories), incubated in peroxidase blocking reagent 
(DakoCytomation) and stained with antisera for Brm (AbCam). Visualization was 
performed using the Vectastain Elite ABC system and 3,3′-diaminobenzidine (Vector 
Laboratories) and hematoxylin. Specimens were evaluated by a clinical pathologist 
according to established guidelines, and the immunoreactivity of Brm was scored according 
to intensity [0 (none), + (low), ++ (moderate), +++ (high)] and extent of tumor staining [0 
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(none), 1 (<25%), 2 (>25%, <50%), 3 (>50%)]. The final Brm score is displayed as a 
composite (intensity + extent). For proliferative indices, antisera against Ki67 
(DakoCytomation) or BrdUrd (Accurate Chemical) was used according to the guidelines of 
the manufacturer. The DeadEnd Colorimeteric TUNEL System (Promega) was employed to 
detect apoptotic cells. For each variable, indices were quantified by counting the total 
positive and negative nuclei in the epithelial layer. A minimum of 1,000 cells were scored 
per mouse for the anterior and ventral prostate lobes, whereas at least 500 cells per mouse 
(due to small size) were tallied for the dorsolateral prostate lobes. Data are presented as the 
mean ± SD. Statistical analyses were performed using ANOVA. Sample size per condition 
and P values are as indicated.
Immunoblots and mRNA analyses
Immunoblots were performed using standard methods that have been previously described 
(26). Briefly, equal protein was separated by SDS-PAGE, transferred to Immobilon PVDF, 
and protein detected using antisera directed against β-actin (sc-1616), probasin (sc-17126), 
E2F1 (sc-193), and E2F4 (sc-1082). Protein was visualized using the Odyssey IR system 
(LiCoR). For mRNA analyses, total RNA was isolated from mouse tissues and fibroblast 
cells using TRIZOL reagent (Invitrogen) and reverse transcribed into cDNA. Amplifications 
were performed with primers directed against E2F1 (sense, 5′-
GACCCTGCAGAACAGATGG-3′; antisense, 5′-GATGTCTCCTGGCATGAGG-3′) and 
18SRNA.
Bioinformatics
Analyses of Brm (SMARCA2) expression were performed with gene expression array data 
from a cohort of nonneoplastic and malignant prostates and the HG-U133A Affymetrix 
platform, as previously described (27). Samples were normalized using the Robust 
Multichip analysis algorithm as implemented in Bioconductor/R (28). Normalized gene 
expression values for each transcript in each sample were set to its ratio relative to the 
expression of that transcript’s measurement in nonneoplastic tissue. Genes that correlated 
(Pearson coefficients, 0.6–1.0) or anticorrelated (Pearson coefficients, −1.0 to −0.6) with the 
average expression of four probesets that map to SMARCA2 in benign tissue, primary 
prostate cancer, and metastatic deposits were determined using GeneSpring GX v7.3.1 
(Agilent Technologies). Statistically overrepresented (P < 0.05) gene ontologies in both 
KEGG and BioCarta pathways were identified using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) 2007 (29).
Results
Brm loss causes lobe-specific prostatic hyperplasia
As SWI/SNF-dependent Brm function has been shown in cultured prostate cancer cells to 
potentially modulate AR activity (22, 23), the importance of Brm in the murine prostate was 
examined. Immunohistochemistry analyses showed that Brm is expressed in all three 
prostate lobes (dorsolateral, DLP; ventral, VP, and anterior, AP), with the highest levels of 
expression observed in the luminal epithelia (Supplementary Fig. S1). To determine the 
effect of Brm status on the prostatic epithelia, mice harboring targeted deletion of the Brm 
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(SMARCA2) locus were used. Consistent with previous reports, Brm−/− mice generated 
offspring with approximate Mendelian frequency (16), and the colony was maintained 
through breeding of heterozygous animals. First, 6-month-old littermates were examined for 
histoarchitecture of the prostate after resection of discrete lobes and H&E staining (Fig. 1). 
As shown, no visible distinctions were noted in the DLP, irrespective of genotype (top). 
Minimal alteration was noted in the VP, although Brm−/− lobes showed sporadic regions of 
epithelial cell tufting (middle). By contrast, marked hypercellularity and loss of organized 
glandular structure with cribriform appearance was observed in the AP (bottom). These 
morphologic changes were compatible with hyperplasia, but no nuclear atypia was observed 
(Supplementary Fig. S2). Thus, Brm loss is sufficient to induce lobe-specific expansion of 
the luminal epithelia.
Given these observations, the underpinning cause of luminal cell alterations was 
investigated by assessing proliferative and apoptotic indices (Fig. 2). As shown in A, the 
proliferative (Ki67) indices of the epithelial compartment within the AP and VP were 
significantly enhanced in glands obtained from Brm−/− mice as compared with Brm+/+ 
littermates (inductions of 2.4-fold and 2.0-fold, respectively). A trend of enhanced 
proliferation was observed in the DLP, but these data did not reach statistical significance, 
consistent with the absence of a consistent pathologic phenotype in this lobe. Together, these 
data suggest that the observed hypercellularity in the AP and modest alterations in VP 
epithelial cell compartments are likely the result of a hyperplastic phenotype. This 
phenotype did not consistently progress to neoplasia over the time period of monitoring (up 
to 12 months of age), as only 1 of more than 20 mice analyzed developed a neoplastic lesion 
(data not shown). Because genetic alterations which induce epithelial cell hyperplasia in the 
murine prostate are often accompanied by an induction in the apoptotic index (30, 31), 
terminal nucleotidyl transferase–mediated nick end labeling (TUNEL) positivity was also 
quantified (Fig. 2B). In these studies, the apoptotic index was elevated in both the AP (2.3-
fold) and VP (5.7-fold) lobes, whereas no alterations were observed in the DLP. Together, 
these data indicate that Brm loss induces lobe-specific hyperplasia that does not consistently 
progress to neoplasia, likely as a result of a concomitant induction in the apoptotic rate.
Brm−/− prostatic epithelia remain androgen-responsive but acquire androgen 
independence
It has been previously shown that androgen ablation causes cell death and/or quiescence of 
the murine prostatic luminal epithelia (32). Cell death induced by androgen ablation is 
complete within 14 days, but repopulation of the luminal epithelia can be induced by re-
supplementation with testosterone (33). Therefore, the effect of Brm disruption on serum 
androgen dependence and androgen responsiveness was examined using the schema 
outlined in Supplementary Fig. S3. Briefly, 3-month-old littermates of each genotype were 
castrated (to induce androgen ablation), and after 14 days, mice were randomized into two 
different cohorts. The first cohort received daily injections of vehicle (to monitor serum 
androgen dependence) for 7 days preceding sacrifice, whereas the second cohort received 
testosterone injections (to monitor androgen responsiveness). In both, BrdUrd was 
administered on the 3rd day of injection, so as to capture the proliferative index of cells after 
castration or re-supplementation. As expected, little BrdUrd incorporation was observed in 
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the epithelia of Brm+/+ animals treated with vehicle alone (Fig. 3A, left bars for each lobe), 
consistent with the serum androgen dependence of these cells. By contrast, there was a trend 
of enhanced BrdUrd incorporation in the Brm−/− epithelia of the AP and DLP, which 
reached statistical significance in the VP (Fig. 3A, right bars), wherein Brm−/− epithelia 
incurred a 9.1-fold induction of BrdUrd incorporation over Brm+/+ controls. These data 
indicate that Brm loss can unexpectedly induce castration-resistant proliferation in a subset 
of epithelia.
Because the transition to castration resistance is frequently associated with a heightened 
sensitivity to androgen, the effect of Brm loss on androgen responsiveness was challenged 
through re-supplementation studies (Fig. 3B). After testosterone re-supplementation, BrdUrd 
indices in each lobe of the Brm−/− mouse were indistinguishable from that observed in Brm
+/+ littermates. These data indicate that androgen signaling remains intact in the absence of 
Brm, and that the proliferative response observed in unchallenged animals is not a result of 
heightened androgen sensitivity. The concept that Brm disruption is sufficient to support 
evidence of castration resistance in vivo was surprising, as studies in cultured cells have 
suggested that AR activity primarily uses Brm-dependent SWI/SNF chromatin remodeling 
activity to support its transactivation function (22, 23), and cells of prostatic origin require 
AR activity. Therefore, to further test this conclusion, AR activity was monitored in Brm−/− 
prostates by assessing levels of a well-defined, prostate-specific AR target gene in the 
mouse, probasin. As shown, no reduction in probasin expression was observed by 
immunoblot (Fig. 3C) or immunohistochemistry (data not shown) in Brm−/− prostates from 
unchallenged mice. Together, these data indicate that Brm loss does not compromise the AR 
response to testosterone, but can induce castration-resistant proliferation in the murine 
prostate.
Brm expression is attenuated in prostate cancer
Because targeted disruption of Brm resulted in hyperplasia and castration-resistance in a 
subset of prostatic epithelia, the status of Brm expression in human prostate cancer was 
initially determined by gene expression profiling of tumor samples that have been 
previously characterized (27). Using four probe sets that map to the 3′-end of the SMARCA2 
transcript, Brm expression was evaluated relative to nonneoplastic tissue (Fig. 4A). As 
shown, a significant decrease in Brm levels was observed in tumor specimens, with the 
lowest expression observed in advanced (metastatic) disease. These findings were validated 
in a second available data set (34), wherein Brm expression was significantly reduced in 
tumor versus nonneoplastic tissue (Supplementary Fig. S4). Analyses revealed that the 
levels of AR target gene expression (KLK3, KLK2, and Nkx3.1) remained unchanged, 
irrespective of Brm levels (Fig. 4B), consistent with observations in the prostates of Brm−/− 
mice. Together, these data indicate that reduced Brm expression is not sufficient to alter AR 
activity in vivo, but is an unexpectedly frequent event in prostate cancer.
To validate these findings, immunohistochemical analyses were first performed on radical 
prostatectomy specimens, wherein matched tumor and nonneoplastic tissues were available 
(n = 34). Although Brm expression levels were variable in nonneoplastic tissue, the protein 
was readily detected in all specimens (Fig. 4C). In matched tumor tissue, attenuation of Brm 
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expression was observed in 47% (16 of 34) of the specimens, wherein Brm levels were 
reduced as compared with matched tissue. Representative immunostaining is provided (top), 
and quantification revealed that tumor-specific reductions in Brm expression occurred 
irrespective of the relative Brm levels in paired nonneoplastic tissue. Finally, Brm levels 
were examined in a larger cohort of tumor specimens using a tissue microarray (n = 72). 
These analyses confirmed that Brm is significantly reduced in prostate cancer as compared 
with nonneoplastic tissues, and that this event can occur even in low-grade disease (Fig. 
4D). Collectively, these data are consistent with observations from gene expression 
analyses, and strongly suggest that Brm down-regulation is a frequent event in prostate 
cancer.
Low Brm expression induces E2F1 deregulation and confers a proliferative advantage
Because Brm expression was lost or reduced with substantive frequency in prostate cancer, 
the consequence of this event was determined in human disease. Initially, tumors quantified 
in Fig. 4C for relative Brm levels were assessed for proliferative indices. As shown in Fig. 
5A, tumors demonstrating reduced Brm expression showed significant induction of the Ki67 
index, as compared with those tumors for which Brm levels were indistinguishable from 
matched nonneoplastic tissue. To validate these results, the effect of Brm status on the 
proliferative index in prostate cancer specimens was determined using a tissue microarray, 
wherein Brm status was inversely proportional to the Ki67 index (Fig. 5B). Together, these 
data are consistent with observations in the Brm−/− mice, and show that Brm attenuation is 
associated with a higher proliferative index in prostate cancer.
As Brm regulates a number of sequence-specific transcription factors, underlying causes of 
the observed hyperplastic phenotypes are likely to be complex. Therefore, gene expression 
analyses were performed using data from the human prostate cancers assessed for Brm 
status in Fig. 4A, in which samples that exhibited either high or low Brm expression were 
used to identify genes that were coordinately regulated. In these analyses, genes were 
identified that correlated (cluster C2, 498 features) or anticorrelated (cluster C1, 422 
features) with Brm mRNA levels (Supplementary Fig. S5A). Functional enrichment analyses 
of each group were performed, and a summary of overrepresented biological pathway 
alterations and gene lists are provided in Supplementary Fig. S5B. Gene lists are provided in 
Supplementary Fig. S6. Given the alterations of proliferative rate observed in Brm−/− mice, 
it was noteworthy that alterations in cell cycle control were observed in tumors with low 
Brm−/− expression. Analyses of corresponding alterations revealed a significant pattern of 
gene regulation that would be predicted to confer a proliferative advantage (summarized in 
Supplementary Fig. S5C) associated with E2F1 deregulation. For example, activation of 
transforming growth factor-β suppresses cell cycle control, mediated in part through the 
ability of Smad2/3 and Smad4 transcriptional complexes to induce the p15ink4b and 
p21cip1 CDK inhibitors (35, 36). Notably, reductions in Smad2 and Smad4 expression were 
associated with Brm loss; conversely, induction of tumor necrosis factor-α (which can 
suppress Smad signaling) also correlated with low Brm expression. These collective data 
indicate that loss of Brm likely relieves the suppression of the cell cycle by facilitating G1 
CDK activity, and it would be predicted that this event would induce excessive RB 
phosphorylation and promote G1 progression. More proximal to this pathway, it was also 
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observed that Brm down-regulation significantly correlated with reduced expression of RB 
itself, and down-regulation of the p27kip1 tumor suppressor. Despite these observations, 
cross-comparison with published data sets of RB target genes revealed that only a subset of 
RB targets were deregulated upon Brm loss (data not shown). Paramount among these was 
E2F1, a critical mediator of both cell cycle progression and cell death, which was induced in 
tumors with low Brm mRNA levels. Indeed, E2F1 anticorrelated with Brm expression (two 
independent probe sets with Pearson correlations of −0.628 and −0.625); in the second data 
set (Supplementary Fig. S4), Pearson coefficients were −0.931 and −0.844. As these data 
potentially implicated Brm as an effector of E2F regulation, E2F1 levels were assessed in 
the murine prostate.
Consistent with expression analyses in human tumors, E2F1 was enhanced in the prostates 
of Brm−/− animals at both the mRNA (Fig. 5D, left) and protein levels (right). Alteration in 
E2F1 activity was specific in this tissue, as no alterations were observed with E2F4. 
Notably, no E2F1 deregulation was observed in tissues reported to be enlarged in Brm−/− 
mice (liver and heart). In addition, no change was observed in tissues not reported to be 
hyperplastic (lung), in tissues that are slightly reduced in size upon Brm loss (testes), or in 
derived murine embryonic fibroblasts (Fig. 5D; Supplementary Fig. S7). Unexpectedly, a 
modest induction of E2F1 was observed in the spleen, which is slightly reduced in size in 
Brm−/− animals. However, the most striking alteration observed was increased E2F1 
expression in the prostate. Thus, E2F1 deregulation in response to Brm loss seems to be 
highly context-specific, and is not required in other tissue types for a hyperproliferative 
phenotype. Together, these data indicate that loss of Brm expression is sufficient to induce 
E2F1 deregulation and hyperproliferation in cells of prostatic origin. In summary, the 
studies herein implicate Brm as a novel suppressor of androgen-dependent proliferation in 
the prostate, and show that Brm loss is sufficient to induce a tissue-specific and E2F1-
associated proliferative advantage in this tissue type.
Discussion
The present study shows that loss of the Brm ATPase is sufficient to induce a hyperplastic 
phenotype in murine models of the prostate and that Brm down-regulation is observed with 
high frequency in prostate cancer. Although, Brm function has been proposed to influence 
AR function in vitro, functional studies in murine models show that AR signaling is retained 
in Brm−/− animals. By contrast, and consistent with a role in prostate cancer progression, 
Brm loss is associated with the transition to castration resistance. These outcomes are 
underpinned by observations in both the Brm−/− prostates and analyses of gene expression 
profiles in human prostate cancer, wherein attenuation of Brm was associated with a high 
proliferative index and E2F1 deregulation. Combined, these data identify Brm as a critical 
modulator of E2F1 expression and growth control in this tissue, and suggest that loss of Brm 
in prostate cancer confers a proliferative advantage.
The demonstration that Brm down-regulation occurs with high frequency in prostate cancer 
was not expected, as Brm−/− mice have not been reported to develop tumors in tissues 
examined previously (16). However, challenge of Brm−/− mice with lung carcinogens was 
reported to increase adenoma formation (37), and loss of Brm expression has been 
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decisively demonstrated in human lung cancer (38). This latter event was shown to occur 
through epigenetic regulation and silencing of Brm mRNA expression. By contrast, recently 
reported Brm loss in gastric cancers occurs as a result of posttranscriptional Brm mRNA 
regulation (39). Although the mechanism by which Brm is down-regulated in human 
prostate cancer remains unexplored, gene expression arrays are suggestive of mRNA 
regulation. While this study was in preparation, a report emerged which suggested that Brg1 
mRNA levels are elevated in prostate cancer, especially under conditions wherein Brm 
expression levels were low (40). Ectopic expression of Brg1 (but not Brm) in cultured cell 
models increased the invasive capacity of AR-negative PC3 cells, therefore further 
suggesting that Brg1 and Brm serve differential functions in cells of prostatic origin. In the 
present study, no significant alteration in Brg1 mRNA was observed in Brm-deficient 
prostate tissues, either in the murine epithelia or in human prostate cancer (data not shown). 
Thus, it is not anticipated that the proliferative phenotypes observed result from Brg1 
deregulation.
The result of Brm down-regulation in both human disease and targeted deletion in murine 
prostates seems to be the induction of a hyperplastic phenotype. Although observed only in 
the VP and AP, lobe-specific hyperplasia is a frequently observed event after oncogenic 
insult in the murine prostate (30, 31). Although the process that contributes to lobe-specific 
outcomes are of interest, our data showing that Brm expression is inversely correlated to the 
proliferative index in prostate cancer and the murine prostate provide compelling evidence 
that Brm loss confers a growth advantage to this tissue. This outcome seems to be tissue-
specific, as previous analyses of Brm−/− animals revealed both organ-specific increases and 
decreases in weight (16). More detailed analyses of proliferative defects in Brm−/− have 
been previously investigated in MEFs, which retain serum dependence, show little change in 
cell cycle kinetics after serum stimulation, and do not form multilayers, but are partially 
compromised in the cellular response to contact inhibition or UV-induced DNA damage 
(16). Whether these phenotypes contribute to the proliferative advantage observed in the 
prostate, and the cause of observed tissue-specific effects in Brm−/− animals, will be the 
focus of future studies.
Particular to prostate cancer, it was surprising to observe that AR signaling was refractory to 
Brm loss, both in the murine prostates and as correlated with Brm down-regulation in human 
disease. Based on studies performed in vitro (22, 23), it was expected that AR activity might 
be compromised upon perturbation of this SWI/SNF subunit. Whether retained AR signaling 
in the absence of Brm is attributed to developmental plasticity remains an unexplored but 
clinically relevant question because AR target gene expression was unaltered in tumors with 
reduced Brm expression. Although Brg1 expression was not enhanced in Brm−/− epithelia, 
it is possible that Brg1-containing complexes are sufficient to sustain AR activity, and/or 
that the chromatin remodeling needs of AR are satisfied by other chromatin remodeling 
complexes. Interestingly, down-regulation of SMARCA3 (HLTF) and SMARCA5 (ISWI/
SNF2H) was significantly observed in conjunction with Brm down-regulation in cancer 
specimens (Supplementary Fig. S6), thus indicating that loss of Brm likely induces the 
perturbation of other chromatin remodeling pathways that may facilitate AR signaling.
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Although AR activity was retained in Brm−/− epithelia (evidenced by sustained probasin 
expression in unchallenged animals and uncompromised response to androgen re-
supplementation), a major implication of the present study is that Brm loss was sufficient to 
induce castration-resistant proliferation in a subset of prostatic epithelia. This may be of 
clinical importance, as the transition to serum androgen independence typically represents 
the development of incurable disease. Based on gene expression profiling of Brm-deficient 
tumors, at least one underlying mechanism is hypothesized to occur through the regulation 
of the retinoblastoma tumor suppressor (RB)/E2F1 axis. Prior studies showed that RB 
directly requires SWI/SNF function to exert negative control over E2F target genes that are 
critical for Sphase progression (41–43); indeed, E2F1 itself is a known E2F target gene. 
Moreover, pathway analyses from human specimens revealed that several upstream 
alterations that would result in RB inactivation (down-regulation of Smad2/3, Smad4, 
p27kip1, and RB itself) likely contribute to the observed induction of E2F1. In the prostate, 
loss of RB function has been shown to convey resistance to androgen ablation and AR 
antagonist therapies in multiple in vitro systems (44), and targeted deletion of RB in 
prostatic epithelia provides a proliferative advantage in vivo (45). Thus, Brm down-
regulation may represent a mechanism to partially suppress RB function in this tissue. 
Because elevated E2F1 is associated with both the induction of cellular proliferation and 
apoptosis (46), these data likely explain the observed outcomes in Brm−/− prostatic 
epithelia. Based on these findings, it is hypothesized that these downstream effects of E2F1 
deregulation may actually hinder the progression of the hyperplastic phenotype, and the 
relevance of this supposition for human disease is being explored.
One additional mechanism that could contribute to the castration-resistant phenotype is 
alterations in local hormone synthesis. Although there are multiple mechanisms that 
contribute to resurgent AR activity in therapy-resistant tumors (25), it is now apparent that a 
substantive percentage of castration-resistant prostate cancers may arise from the activation 
of intracrine de novo androgen synthesis within the tumor microenvironment (47–49). 
Indeed, analysis of patients with recurrent tumors after hormone therapy supports this 
contention, and the recent observation that an irreversible Cyp17 inhibitor, abiraterone, can 
reduce prostate-specific antigen in patients that failed hormone therapy highlights the 
clinical relevance of this supposition (50). It is of interest that four effectors of C21 steroid 
hormone metabolism (Cyp11A1, which generates pregnenolone from cholesterol; Cyp11B2, 
which converts corticosterone to aldosterone; Cyp17A1, which assists pregnenolone and 
DHEA production, but has also been recently implicated in a backdoor pathway for steroid 
production; and Cyp21A7, which hydroxylates progesterone) were anticorrelated with Brm 
levels in gene expression arrays from human tumors. Thus, alterations in Brm may affect 
steroid hormone synthesis. However, serum testosterone levels were indistinguishable from 
Brm-positive animals in castration/re-supplementation studies (Supplementary Fig. S3B). As 
such, the current data do not support the contention that Brm loss increases serum 
testosterone levels; however, the local effect within the prostate cannot be excluded and is 
the focus of ongoing study.
In summary, the data presented herein show that Brm loss results in prostate-specific 
hyperplasia, the transition to androgen independence, and deregulated E2F1 expression after 
Shen et al. Page 10
Cancer Res. Author manuscript; available in PMC 2010 April 23.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
targeted ablation in murine tissues. These events hold consequence in human disease, 
wherein down-regulation of Brm is associated with a high proliferative index. Together, 
these data reveal a putative tumor suppressor function for Brm in the prostate, and suggest 
that loss of this protein is sufficient to confer a proliferative advantage in this tissue.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Brm loss causes lobe-specific disruption of glandular structures in the murine prostate. H&E 
sections of the DLP, VP, and AP from 6-month-old littermates.
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Figure 2. 
Brm loss induces hyperplasia of the prostatic epithelia. A, the proliferative indices of Brm
+/+ and Brm−/− littermates were determined in unchallenged 6-month-old animals by 
immunostaining for Ki67. At least 1,000 cells were tallied per animal by a blinded observer 
for each AP and VP. In the DLP, at least 500 cells were scored per animal, due to the small 
size of this lobe. Averages, SD, and n numbers are as indicated. A representative example of 
the AP is provided (bottom). B, lobes in A were processed to detect apoptotic indices by 
TUNEL staining.
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Figure 3. 
AR signaling is retained in Brm−/− epithelia, and is accompanied by castration-resistant 
proliferation. A, androgen-independent proliferative indices were determined by quantifying 
BrdUrd incorporation rates after castration (oil cohort). At least 500 epithelial cells per AP 
and VP or 150 per DLP were scored per animal. One DLP was excluded from analyses due 
to its inability to obtain sufficient cell numbers for counting. Columns, mean; bars, SE. B, 
androgen dependent (AR dependent) proliferation indices were determined in the 
testosterone cohort, as described in A. C, probasin (AR target gene) expression was 
monitored by immunoblot from the prostates of 6-month-old or 10-month-old intact 
animals, as indicated. Actin was included as a loading control.
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Figure 4. 
Tumor-specific loss of Brm mRNA and protein is observed in human prostate cancers. A, 
Brm (SMARCA2) expression was analyzed in benign prostatic hyperplasia (n = 6), primary 
prostatic adenocarcinomas (n = 79), and metastatic samples of prostate cancer (n = 8; 
bottom). The relative expression levels as compared with nonneoplastic controls are shown, 
as determined using all SMARCA2 probe sets that map to the 3′-end of the gene. B, using 
gene expression analyses for tumors in A, the relative association between SMARCA2 status 
(using four probe sets, green bar) and AR target gene expression (Nkx3.1, KLK2, and KLK3) 
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was assessed. C, analyses of Brm protein levels in matched nonneoplastic and primary 
prostate cancer specimens. Top, representative immunostaining. Bottom, quantification of 
expression from 34 matched samples using a 0 to 3 scale based on the intensity of 
immunohistochemistry. Relative expression and n for each category. Red dotted lines, the 
cohorts in which Brm expression was unchanged relative to nonneoplastic; black lines, 
tumor specimens for which Brm levels were reduced. D, relative Brm expression as a 
function of Gleason grade, as obtained by tissue microarray. Bars, mean.
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Figure 5. 
Brm loss induces E2F1 deregulation and confers a proliferative advantage in the prostate. A, 
specimens determined in Fig. 4C as having a tumor-specific loss of Brm expression (N > T) 
or no change in Brm expression relative to matched nonneoplastic samples (N = T) were 
analyzed in serial sections for Ki67 indices. B, serial sections from tissue microarray(n = 36) 
were analyzed to quantify relative Brm and Ki67 expression. C, representation of 
statistically overrepresented gene pathways that are altered as a function of Brm status 
(determined using the samples described in Fig. 4A and identified as per Supplementary 
Figs . S5 and S6 using DAVID). D, relative mRNA expression of E2F1 in tissues from Brm
+/+ and Brm−/− littermates (left); protein expression of E2F1, E2F4, and β-actin (loading 
control) was monitored in prostates from 6-month-old or 10-month-old Brm+/+ and Brm−/− 
littermates by immunoblot (right).
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